Cell labelling for in vivo use and in process quality control

由Altrika、爱丁堡大学化学学院、Roslin Cellab和Barts以及The London组成的联盟，带来了研发、制造、临床和商业化的经验，以应对在体外和体内追踪临床相关细胞群的挑战。缺乏体内跟踪方法导致研发、制造和临床限制，宝贵的研究人员时间和细胞产量损失，以及相关成本。该项目采用了一种创新的，无毒的细胞标签，稳定，具有成本效益，易于检测。它将证明对一系列再生医学疗法的适用性，以满足未满足的临床需求，并提高研发活动和制造过程的效率，并提高临床交付的有效性。考虑到再生医学的发展，到2020年，这个平台可以减少高达2.75亿美元的行业成本。

The consortium of Altrika, the University of Edinburgh’s School of Chemistry, Roslin Cellab and Barts and The London bring R&D, manufacturing, clinical and commercialisation experience to the challenge of tracking clinically relevant cell populations in vitro and in vivo. The absence of an in vivo tracking methodology leads to R&D, manufacturing and clinical constraints, valuable researcher time and cell yield losses, and associated costs. This project utilises an innovative, non-toxic cell label that is stable, cost-effective and easy to detect. It will demonstrate applicability to a range of regenerative medicine therapies for unmet clinical needs, as well as increasing the efficiency of R&D activities and manufacturing processes, and improving the efficacy of clinical delivery. Given the growth of regenerative medicine, this platform could reduce industry costs by as much as $275m in 2020.